

Provider website additions — COVID-19 therapeutics

COVID-19 pre-exposure prophylaxis treatment for some immunocompromised individuals

Evusheld (tixagevimab co-packaged with cilgavimab):

- Evusheld was granted emergency use authorization (EUA) in December 2021 for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and pediatric individuals (12 years of age and older weighing at least 40 kg) who may not mount an adequate immune response to COVID-19 vaccination or in whom COVID-19 vaccination is not recommended due to a history of severe adverse reaction.
- Evusheld is given as an initial dose of two consecutive intramuscular (IM) injections with repeat doses every six months.
- Additional information about medical conditions and/or medications that allow an individual to qualify for Evusheld can be found on page four of the *Fact Sheet for Healthcare Providers: Emergency Use Authorization For Evusheld*, available at <https://www.fda.gov/media/154701/download>.
- **Update: In November 2022, the FDA’s EUA Fact Sheet for Healthcare Providers was updated to include information about reduced efficacy of Evusheld against currently circulating variants.**

Medi-Cal Managed Care (Medi-Cal) in-network sites where Evusheld is offered (updated as of September 1, 2022):

Provider name	Address 1	City	County	State code	ZIP
John Muir Medical Center Walnut Creek	1601 Ygnacio Valley Rd.	Walnut Creek	Contra Costa	CA	94598
Eden Medical Center	20103 Lake Chabot Rd.	Castro Valley	Alameda	CA	94546
St. Elizabeth Community Hospital	2550 Sister Mary Columba Dr.	Red Bluff	Tehama	CA	96080
Desert Regional Medical Center	1150 North Indian Canyon Dr.	Palm Springs	Riverside	CA	92262
Beverly Hospital	309 W Beverly Blvd.	Montebello	Los Angeles	CA	90640
Adventist Health White Memorial	1720 E. Cesar E Chavez Ave.	Los Angeles	Los Angeles	CA	90033
Valley Children’s Healthcare	9300 Valley Children’s Place	Madera	Madera	CA	93636
Lucile Packard Children’s Hospital	725 Welch Rd.	Palo Alto	Santa Clara	CA	94304
Mercy Med Center Redding	2175 Rosaline Ave.	Redding	Shasta	CA	96001
Huntington Hospital	100 W. California Blvd.	Pasadena	Los Angeles	CA	91105
UCSF Benioff Children’s Hospital Oakland	747 52nd St.	Oakland	Alameda	CA	94609

<https://providers.anthem.com/ca>

Provider name	Address 1	City	County	State code	ZIP
Centinela Hospital Medical Center	555 East Hardy St.	Inglewood	Los Angeles	CA	90301
Alta Bates Summit Medical Center	2450 Ashby Ave.	Berkeley	Alameda	CA	94705
San Antonio Regional Hospital	999 San Bernardino Rd.	Upland	San Bernardino	CA	91786
California Pacific Medical Center	1101 Van Ness Ave Inpatient	San Francisco	San Francisco	CA	94109
Martin Luther King Jr. Community Ho	1680 E 120th St.	Los Angeles	Los Angeles	CA	90059
LAC-USC Medical Center	1200 N State St Rm B2a100	Los Angeles	Los Angeles	CA	90033
Mission Community Hospital	14850 Roscoe Blvd. Pharmacy	Panorama City	Los Angeles	CA	91402
Hoag Mem Hosp Pnb	1 Hoag Dr	Newport Beach	Orange	CA	92663
Mammoth Hospital	85 Sierra Park Rd.	Mammoth Lakes	Mono	CA	93546
UC Davis Medical Center	2315 Stockton Blvd - Room 0761	Sacramento	Sacramento	CA	95817
Mills Peninsula Medical Center	1501 Trousdale Dr.	Burlingame	San Mateo	CA	94010
Highland Hospital	1411 East 31st St.	Oakland	Alameda	CA	94602
Keck Hospital Of USC	1500 San Pablo St.	Los Angeles	Los Angeles	CA	90033
California Hospital Medical Center	1401 S Grand Ave.	Los Angeles	Los Angeles	CA	90015
Children's Hospital Los Angeles	4650 W Sunset Blvd.	Los Angeles	Los Angeles	CA	90027
Antelope Valley Medical Center	1600 W Ave. J	Lancaster	Los Angeles	CA	93534
Oroville Hospital	2767 Olive Hwy	Oroville	Butte	CA	95966
Saint Agnes Medical Center	1303 East Herndon Ave.	Fresno	Fresno	CA	93720
Children's Hospital Of Orange County	1201 W. La Veta Ave.	Orange	Orange	CA	92868
UCSF Medical Center	505 Parnassus Ave.	San Francisco	San Francisco	CA	94143

COVID-19 treatment options for individuals who have tested positive for COVID-19

Paxlovid (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use:

- Paxlovid was granted EUA in December 2021 for treatment of mild to moderate COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) with positive COVID-19 test results and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid should be started within five days of symptom onset.
- Paxlovid is given as an oral dose of two nirmatrelvir tablets with one ritonavir tablet, with all three tablets taken together twice daily for five days. Dose reduction for moderate renal impairment is available. Paxlovid is not recommended for individuals with severe renal or hepatic impairment.

- Additional information about underlying medical conditions associated with higher risk for severe COVID-19 can be found on the CDC website at <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>.
- Additional information about contraindications and drug interactions can be found in the *Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid* at <https://labeling.pfizer.com/ShowLabeling.aspx?id=16474&format=pdf>.

Lagevrio (molnupiravir) capsules, for oral use:

- Lagevrio was granted EUA in December 2021 for treatment of mild to moderate COVID-19 in adults (18 years of age or older) with positive COVID-19 test results and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. Lagevrio should be started within five days of symptom onset.
- Lagevrio is given as an oral dose taken every 12 hours for five days.
- Additional information about Lagevrio can be found in the *Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio (molnupiravir) Capsules* at <https://www.merck.com/eua/molnupiravir-hcp-fact-sheet.pdf>.

Bebtelovimab:

- Bebtelovimab was granted EUA in February 2022 for outpatient treatment of mild to moderate COVID-19 in adults and children (age 12 years and older and weighing at least 40 kg) who are high risk for progressing to severe COVID-19 and/or hospitalization and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. Bebtelovimab is not authorized for patient who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.
- Bebtelovimab is given as a single intravenous (IV) injection over at least 30 seconds and should be given within seven days of symptom onset.
- Additional information about Bebtelovimab can be found in the *Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab* at <https://www.merck.com/eua/molnupiravir-hcp-fact-sheet.pdf>.
- **Update: On November 30, 2022, the FDA announced that Bebtelovimab is not currently authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. More information can be found on the FDA website at <https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region>.**

Veklury (remdesivir):

- Remdesivir was granted EUA in May 2020, and full FDA approval in October 2020 for the treatment of COVID-19 in hospitalized adults and children (weighing at least 3.5 kg, with an adjusted dose for children weighing over 3.5 kg and under 40 kg). In January 2021, FDA approval for remdesivir was expanded to include outpatient treatment of adult and pediatric individuals with COVID-19 at high risk of being hospitalized.
- Remdesivir is given as an IV infusion once daily for three days in the outpatient setting and for up to five days in the inpatient setting and should be given within seven days of symptom onset.
- Additional information about remdesivir can be found in the *Fact Sheet for Healthcare Providers: Emergency Use Authorization of Veklury (remdesivir)* at <https://www.fda.gov/media/143189/download>.

List of in network sites providing Bebtelovimab (updated as of September 1, 2022):

- There are no longer sites providing Bebtelovimab as of November 30, 2022.

COVID-19 symptoms and testing

COVID-19 symptoms:

- People with COVID-19 can have a wide range of symptoms, from mild to severe, that may appear between 2 to 14 days after exposure.
- Symptoms include:
 - Fevers or chills.
 - Cough.
 - Shortness of breath or difficulty breathing.
 - Fatigue.
 - Muscle or body aches.
 - Headache.
 - New loss of taste or smell.
 - Sore throat.
 - Congestion or runny nose.
 - Nausea or vomiting.
 - Diarrhea.
- Additional information about COVID-19 symptoms can be found on the CDC website: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.

Testing for COVID-19:

- People who are experiencing any of the above symptoms or who have had an exposure to COVID-19 should be tested for COVID-19.
- Additional information about COVID-19 testing can be found on the CDC website: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html>.

List of test to treat sites

Test to treat sites are locations where individuals are able to get tested for COVID-19 and — if they are positive and treatments are appropriate for them — are able to get a prescription from a healthcare provider and fill that prescription all in one location. Oral COVID-19 medications should be started within five days of the start of COVID-19 symptoms.

Test to treat sites in California: <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

Testing for COVID-19

Testing sites in California: <https://myturn.ca.gov/testing.html>

National Institutes of Health (NIH) COVID-19 treatment guidelines

<https://www.covid19treatmentguidelines.nih.gov/>

Federal Health and Human Services (HHS) COVID-19 therapeutics locator

<https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>

California Department of Public Health (CDPH) COVID-19 treatment resources for healthcare providers

<https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Treatment-Resources-for-Providers.aspx>

How to register as a test to treat provider

For information about how to register as a test to treat provider and how to receive information directly from your local health jurisdiction, please visit <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Become-Test-to-Treat-Site.aspx>